Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies

摘要: Abstract Background Managing elderly patients with type 2 diabetes poses particular challenges, so it is important to evaluate the efficacy and tolerability profile of antidiabetic therapies specifically in this patient population. Objective The aim our study was compare liraglutide, a GLP-1 analog, (≥65 years) younger ( Methods A pooled analysis 6 randomized, placebo-controlled, multinational trials included data from 3967 aged18 80 years glycosylated hemoglobin (HbA 1c ) 7% 11%. Of these, 552 ≥65 received liraglutide 1.8 mg, 1.2 or placebo; 2231 , fasting plasma glucose, body weight, blood pressure: as marked identify elements tracked for change baseline; hypoglycemic episodes; adverse events. Results Reduction HbA baseline significantly greater mg versus placebo (least squares mean difference: years, 0.91% [95% CI, 0.69–1.12]; P Conclusion Liraglutide provides effective glycemic control well tolerated